Nuclivision featured in the news
January 27, 2025
Nuclivision was highlighted by Trends Kanaal Z as 'starter of the week', a category in their business magazine featuring promising startups.
January 27, 2025
Nuclivision was highlighted by Trends Kanaal Z as 'starter of the week', a category in their business magazine featuring promising startups.
In its first news feature, Nuclivision was highlighted by Trends Kanaal Z as "Starter of the Week," a category in their business magazine that showcases promising startups. This recognition underscores our mission to innovate nuclear medicine with safer and more efficient imaging technology.
For the full article in Dutch, visit the Trends Kanaal Z website: Read the original article.
Two days later, Nuclivision was featured in a video news report highlighting the milestone of €1 billion in follow-up funding raised collectively by all imec.istart portfolio companies. As proud members of the accelerator program, our CEO, Maarten Larmuseau, was invited to share his insights on the most valuable aspects of the program for startups like ours.
Find out what he had to say in the full report: Watch the video.
PET scans help doctors detect inflammation and tumors at an early stage. This imaging technique involves injecting a mildly radioactive substance into the body. However, the associated radiation poses some risk to the patient. Ghent-based Nuclivision has developed a technology that requires less radioactive material for such scans.
"Our solution is based on recent advancements in deep learning, a subfield of artificial intelligence, applied to medical imaging," says engineer and CEO Maarten Larmuseau. "We currently have competitors in the U.S. and Asia, but our technology is the most recent. With this, we aim to meet the specific needs of nuclear medicine in Europe."
"Our solution has been tested for some time in hospitals in Belgium, France, and the Netherlands. In a few months, we expect to obtain CE certification, which will allow us to commercialize our solution across Europe. This is crucial because, given the small Belgian market, Nuclivision must expand internationally."
"COO Tomas Brants and I founded Nuclivision in September 2022. Six months later, we were joined by CTO Simon DeKeyser. The company was co-founded by professors and medical experts in nuclear medicine and medical imaging, providing us with strong expertise and industry connections."
"We are part of the imec.istart and Start it@KBC accelerator programs, as well as the Wintercircus technology hub. Through imec.istart and the Lumiares fund, we secured pre-seed funding. Additionally, VLAIO has supported us in improving our product through targeted scientific research."
A new perspective on nuclear medicine. Our software solutions assist physicians along their entire workflow, from image acquisition to diagnosis and follow-up.
